Literature DB >> 19009369

Diagnostic value of prostate-specific antigen (PSA) and free prostate specific antigen (fPSA) in women with ovulatory and anovulatory polycystic ovary syndrome.

Kubilay UKINC1, Halil Onder Ersoz, Cihangir Erem, Arif Bayram Hacihasanoglu.   

Abstract

Diagnosis of polycystic ovary syndrome (PCOS) is very difficult in women with ovulatory cycles. We assessed the diagnostic value of prostate-specific antigen (PSA) and free prostate-specific antigen (fPSA) in women with ovulatory or anovulatory PCOS. Study group consisted of 62 women with PCOS and 35 healthy female controls. PCOS group was divided into two subgroups as anovulatory (n = 42; 68%, Group A) and ovulatory group (n = 20; 32%, Group B). A cut-off level of PSA and fPSA was established for the sensitivity, specificity, positive likelihood ratio, area under curve, diagnostic accuracy, and positive and negative predictive values of diagnosis of PCOS. In group A, a PSA level of greater than 10 pg/ml yielded a sensitivity of 73.2%, a specificity of 80%, and a diagnostic accuracy of 73%, with a positive predictive value of 88.2% and a negative predictive value of 59.3%. An fPSA level of greater than 2.1 pg/ml yielded a sensitivity of 71.2%, a specificity of 80.4%, and a diagnostic accuracy of 87%, with a positive predictive value of 87.2% and a negative predictive value of 58.4%. In group B, a PSA level of greater than 10 pg/ml yielded a sensitivity of 65%, a specificity of 80%, and a diagnostic accuracy of 73%, with a positive predictive value of 76.5% and a negative predictive value of 69.6%. An fPSA level of greater than 2.1 pg/ml yielded a sensitivity of 65.4%, a specificity of 80.4%, and a diagnostic accuracy of 87%, with a positive predictive value of 75.5% and a negative predictive value of 68.4%. Circulating androgens and hirsutism are independently associated with the degrees of PSA and fPSA in PCOS women. Increased plasma levels of PSA (>10 pg/ml) and fPSA (>2.1 pg/ml) could be helpful as a diagnostic tool for women with ovulatory or anovulatory PCOS.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19009369     DOI: 10.1007/s12020-008-9130-6

Source DB:  PubMed          Journal:  Endocrine        ISSN: 1355-008X            Impact factor:   3.633


  23 in total

1.  A critical evaluation of simple methods for the estimation of free testosterone in serum.

Authors:  A Vermeulen; L Verdonck; J M Kaufman
Journal:  J Clin Endocrinol Metab       Date:  1999-10       Impact factor: 5.958

2.  The best correlation of the new index of hyperandrogenism with the grade of increased body hair.

Authors:  D Cibula; M Hill; L Starka
Journal:  Eur J Endocrinol       Date:  2000-09       Impact factor: 6.664

3.  Antiandrogen drugs lower serum prostate-specific antigen (PSA) levels in hirsute subjects: evidence that serum PSA is a marker of androgen action in women.

Authors:  C Negri; F Tosi; R Dorizzi; A Fortunato; G G Spiazzi; M Muggeo; R Castello; P Moghetti
Journal:  J Clin Endocrinol Metab       Date:  2000-01       Impact factor: 5.958

Review 4.  Polycystic ovary syndrome: a changing perspective.

Authors:  S Franks
Journal:  Clin Endocrinol (Oxf)       Date:  1989-07       Impact factor: 3.478

Review 5.  Androgens in polycystic ovarian syndrome.

Authors:  M Pugeat; M H Nicolas; J C Craves; C Alvarado-Dubost; S Fimbel; H Déchaud; H Lejeune
Journal:  Ann N Y Acad Sci       Date:  1993-05-28       Impact factor: 5.691

6.  Prostate-specific antigen and human glandular kallikrein 2 are markedly elevated in urine of patients with polycystic ovary syndrome.

Authors:  C V Obiezu; A Scorilas; A Magklara; M H Thornton; C Y Wang; F Z Stanczyk; E P Diamandis
Journal:  J Clin Endocrinol Metab       Date:  2001-04       Impact factor: 5.958

7.  Prostate-specific antigen in female serum, a potential new marker of androgen excess.

Authors:  D N Melegos; H Yu; M Ashok; C Wang; F Stanczyk; E P Diamandis
Journal:  J Clin Endocrinol Metab       Date:  1997-03       Impact factor: 5.958

Review 8.  Prostate-specific antigen (PSA) in women.

Authors:  H Yu; H Berkel
Journal:  J La State Med Soc       Date:  1999-04

9.  Prevalence of the polycystic ovary syndrome in unselected black and white women of the southeastern United States: a prospective study.

Authors:  E S Knochenhauer; T J Key; M Kahsar-Miller; W Waggoner; L R Boots; R Azziz
Journal:  J Clin Endocrinol Metab       Date:  1998-09       Impact factor: 5.958

Review 10.  Molecular forms of prostate-specific antigen and the human kallikrein gene family: a new era.

Authors:  R T McCormack; H G Rittenhouse; J A Finlay; R L Sokoloff; T J Wang; R L Wolfert; H Lilja; J E Oesterling
Journal:  Urology       Date:  1995-05       Impact factor: 2.649

View more
  3 in total

1.  A Study on Omentin-1 and Prostate Specific Antigen in Women on Treatment for Polycystic Ovary Syndrome.

Authors:  Anbalagan Anithasri; Palghat Harihara Ananthanarayanan; P Veena
Journal:  Indian J Clin Biochem       Date:  2017-12-11

2.  Diagnostic value of prostate-specific antigen in women with polycystic ovary syndrome.

Authors:  Farahnaz Mardanian; Nasrin Heidari
Journal:  J Res Med Sci       Date:  2011-08       Impact factor: 1.852

Review 3.  Prostatic-specific antigen (PSA) levels in patients with polycystic ovary syndrome (PCOS): a meta-analysis.

Authors:  Zeng-Hong Wu; Yun Tang; Xun Niu; Fei-Fei Pu; Xi-Yue Xiao; Wen Kong
Journal:  J Ovarian Res       Date:  2019-10-15       Impact factor: 4.234

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.